A
Anna Ida Fiaschi
Researcher at University of Siena
Publications - 54
Citations - 1171
Anna Ida Fiaschi is an academic researcher from University of Siena. The author has contributed to research in topics: Glutathione reductase & Glutathione peroxidase. The author has an hindex of 16, co-authored 54 publications receiving 991 citations.
Papers
More filters
Journal ArticleDOI
Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats.
Margherita Neri,Daniela Cerretani,Anna Ida Fiaschi,Pasini Franco Laghi,Pietro Euea Lazzerini,Angela Bruna Maffione,Lucia Micheli,Giancarlo Bruni,Cristina Nencini,Giorgio Giorgi,Stefano D'Errico,Carmela Fiore,Cristoforo Pomara,Irene Riezzo,Emanuela Turillazzi,Vittorio Fineschi +15 more
TL;DR: The hypothesis that catecholamines may induce oxidative damage through reactive intermediates resulting from their auto‐oxidation, irrespective of their interaction with adrenergic receptors, is supported, thus representing an important factor in the pathogenesis of catecholinamines‐induced cardiotoxicity.
Journal ArticleDOI
Diffuse Axonal Injury and Oxidative Stress: A Comprehensive Review.
Alessandro Frati,Daniela Cerretani,Anna Ida Fiaschi,Paola Frati,Vittorio Gatto,Raffaele La Russa,Alessandro Pesce,Enrica Pinchi,Alessandro Santurro,Flavia Fraschetti,Vittorio Fineschi +10 more
TL;DR: Following TBI, axonal degeneration has been identified as a progressive process that starts with disrupted axonal transport causing axonal swelling, followed by secondary axonal disconnection and Wallerian degeneration, and studies support the role of an altered axonal calcium homeostasis as a mechanism in the secondary damage of axon, and suggest that calcium channel blocker can alleviate the secondaryDamage.
Journal Article
Glutathione, ascorbic acid and antioxidant enzymes in the tumor tissue and blood of patients with oral squamous cell carcinoma.
TL;DR: The enhanced antioxidant capacities in tumor tissues can make them less susceptible to oxidative stress, conferring a selective growth advantage on tumor cells.
Journal ArticleDOI
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer
TL;DR: The majority of reviewed studies reported a pain reduction in >50% of patients receiving Dox or Epi, suggesting a substantial palliative effect by their use in metastatic HRPC, suggesting the combination of docetaxel with active agents such as anthracyclines may deserve further clinical investigation.
Journal ArticleDOI
Apatinib for the treatment of gastric cancer
Giandomenico Roviello,Andrea Ravelli,Anna Ida Fiaschi,Maria Rosa Cappelletti,Angela Gobbi,Chiara Senti,Laura Zanotti,Karol Polom,Andrew R. Reynolds,Stephen B. Fox,Daniele Generali +10 more
TL;DR: This review focuses on the mechanism of action of apatinib, its pharmacokinetic profile and its clinical activity in the treatment of advanced/metastatic gastric cancer.